Latest Breaking News On - Transfusion dependent beta thalassemia - Page 6 : comparemela.com

Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition

BOSTON (BUSINESS WIRE) Dec 11, 2023

United statesSaudi arabiaCity ofUnited kingdomGreat britainExagamglogene autotemcelHeather nicholsManisha paiCarmen bozicExchange commissionGlobal medicines developmentVertex pharmaceuticals incorporated nasdaqAmerican society of hematologyVertex pharmaceuticals incorporatedDrug agencyOcclusive crisis on health

Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Pres

- Longer-term follow-up data demonstrate consistent and durable response to treatment -BOSTON (BUSINESS WIRE) Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced two oral presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition from the global pivotal trials of CASGEVY.

Saudi arabiaUnited kingdomCity ofUnited statesGreat britainManisha paiHeather nicholsExagamglogene autotemcelCarmen bozicOcclusive crisis on healthNational health regulatory authorityDrug administrationRegulatory agencyImprovements in healthVertex pharmaceuticals incorporatedDrug agency

RoslinCT to manufacture first-ever US FDA approved CRISPR-based gene therapy CASGEVY™ (exagamglogene autotemcel)

RoslinCT to manufacture first-ever US FDA approved CRISPR-based gene therapy CASGEVY™ (exagamglogene autotemcel) RoslinCT to manufacture this grou.

United statesSaudi arabiaCity ofUnited kingdomGreat britainJessica hodgsonPeter colemanAmber fennellRegulatory agencyRoslin instituteManufacturing organisationEuropean medicines agencyContract developmentDrug administrationNational health regulatory authorityDrug agency

Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar

All RUBY patients with ≥5 months follow-up have achieved a normal hemoglobin level and a fetal hemoglobin level of

United statesUnited kingdomSan diegoSan diego convention centerBaisong meiRabi hannaBroad instituteAmerican society of hematologyDivision of pediatric hematology oncologyHarvard university casEuropean hematology associationEditas medicine incBroad institute casExchange commissionDepartment of pediatric hematology oncologyAnnual congress

Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar

Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesUnited kingdomSan diego convention centerRabi hannaBaisong meiCristi barnettDepartment of pediatric hematology oncologyHarvard university casBroad institute casGlobenewswire incAmerican society of hematologyBroad instituteEditas medicine incExchange commissionDivision of pediatric hematology oncology